electroCore Announces Positive Top-Line Results from Premium II Migraine Prevention Study
Emergency Use Authorization (EUA)
gammaCore SapphireTM CV (nVNS) receives EUA to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
See an Essential Conversation about the Covid-19 Crisis and gammaCore SapphireTM CV (nVNS)
See COVID-19 Patient Management at Home and Hospital Today
The science of
nVNS
nVNS therapy stimulates the vagus nerve, which has been proven to help people suffering from a variety of disorders.
Pioneers of technology. Innovators of medicine.
We are pioneering the use of nVNS to deliver bioelectronic medicine for patient benefit.
Our Product. Our Passion.
gammaCore™ (non-invasive vagus nerve stimulator) has become a solution for many people.
For payers
Take a few minutes to read 5 articles in support of coverage for gammaCore. We are committed to ensuring that appropriate patients have uninterrupted access to gammaCore.
electroCore is committed to the safety and care of our patients, providers, and employees during the COVID-19 pandemic. We have implemented several operational enhancements, research initiatives, and virtual capabilities to ensure patients who depend on us have uninterrupted access to gammaCoreTM (non-invasive vagus nerve stimulator). To learn more about our efforts please call (888) 903-CORE.
By clicking “Accept” you are agreeing to eletroCore to place cookies on your browser to gather web statistics that help us improve our site experience. Please read our Privacy Policy for more information on the types of cookies we use.
